Category: Publicity

Biotech Investors Should Consider The Four Horsemen

Biotech Investors Should Consider The Four Horsemen

One of the keys to long-term biotech investing is finding the big winners and riding them to huge gains, writes Medical Technology Stock Letter editor John McCamant and frequent MoneyShow.com contributor. Medical Technology Stock Letter has had many such winners over the years, including Genentech and Pharmacyclics. We provided multiple entry points to invest in Pharmacyclics starting at $17 and in three-plus years the company was sold to AbbVie for $262 per share or $21 billion. Over the last year and a quarter, our subscribers have been enjoying incredible gains with the Four Horsemen: Esperion Therapeutics. Madrigal Pharmaceuticals, Nektar Therapeutics, Sangamo Therapeutics.

Posted on by

MoneyShow’s Top Stock Pickers of 2017

Biotechnology expert John McCamant deserves special recognition; his top pick from last year rose an astounding 519%. We’ve asked John, and all these other outstanding advisors, to share their updated opinions on these top performing stocks from last year’s Top Picks 2017 report.

Posted on by

Trump Victory Brings V-Shaped Reaction (11-9-16)

The immediate reaction of a widely unexpected Republican sweep was a huge across the board rally in health care stocks. While it is still very early make definitive conclusions, several positive impacts have resulted in a major reversal of sentiment. Today’s impressive rally (NBI +8%) is a likelihood of some combination of the following macro fundamental and technical changes that are expected to occur with a new, right leaning administration.

Posted on by